PMID- 33733963
OWN - NLM
STAT- MEDLINE
DCOM- 20220309
LR  - 20220531
IS  - 1477-0377 (Electronic)
IS  - 1358-863X (Linking)
VI  - 26
IP  - 3
DP  - 2021 Jun
TI  - Outcomes of the paclitaxel-eluting Eluvia stent for long femoropopliteal lesions 
      in Asian patients with predominantly chronic limb-threatening ischemia.
PG  - 267-272
LID - 10.1177/1358863X20987894 [doi]
AB  - The fluoropolymer-coated, paclitaxel-eluting Eluvia stent has shown promising 
      results for the endovascular treatment of femoropopliteal artery lesions in 
      patients with claudication. The aim of the current study was to evaluate efficacy 
      and safety outcomes of the Eluvia stent for the treatment of long femoropopliteal 
      lesions in Asian patients. This is a single-center, retrospective study. The 
      primary endpoint was primary patency at 1 year. Secondary outcomes were 30-days 
      complication rate, technical success, 1-year freedom from clinically driven 
      target lesion revascularization (CD-TLR), limb salvage, survival, amputation-free 
      survival (AFS), wound healing, and clinical improvement. A total of 64 patients 
      with 67 femoropopliteal lesions were included; 78% suffered from diabetes and 84% 
      had chronic limb-threatening ischemia (CLTI). Of those with ischemic wounds, 79% 
      did not have run-off to the foot. Mean lesion length was 193 +/- 128 mm and 52% 
      were severely calcified. Primary patency at 1 year was 84% in the overall cohort 
      and 91% in patients with complete lesion coverage with the Eluvia stent. 
      Technical success was achieved in 100% of the cases and 30-day complications 
      occurred in six patients. Twelve-month freedom from CD-TLR, limb salvage, 
      survival, and AFS were 92%, 93%, 85%, and 80%, respectively. In 80% of patients, 
      complete wound healing was experienced and 84% had clinical improvement after 1 
      year. The Eluvia stent showed promising 12-month patency and clinical results for 
      femoropopliteal treatment in this CLTI-dominant patient population with severely 
      calcified, long lesions. Patient numbers were, however, small; larger trials are 
      required to validate these findings. Aneurysmal change seen in some cases also 
      needs further investigation.
FAU - Kum, Steven
AU  - Kum S
AD  - Department of Surgery, Changi General Hospital, Singapore.
FAU - Ipema, Jetty
AU  - Ipema J
AD  - Department of Vascular Surgery, Northwest Clinics, Alkmaar, The Netherlands.
FAU - Huizing, Eline
AU  - Huizing E
AUID- ORCID: 0000-0002-5297-2640
AD  - Department of Vascular Surgery, Northwest Clinics, Alkmaar, The Netherlands.
FAU - Tan, Yih K
AU  - Tan YK
AD  - Department of Surgery, Changi General Hospital, Singapore.
FAU - Lim, Darryl
AU  - Lim D
AD  - Department of Surgery, Changi General Hospital, Singapore.
FAU - Lok, Ian Yh
AU  - Lok IY
AD  - University of New South Wales, Sydney, NSW, Australia.
FAU - Hazenberg, Constantijn Evb
AU  - Hazenberg CE
AD  - Department of Surgery, Division of Vascular Surgery, University Medical Center 
      Utrecht, Utrecht, The Netherlands.
FAU - Unlu, Cagdas
AU  - Unlu C
AD  - Department of Vascular Surgery, Northwest Clinics, Alkmaar, The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210318
PL  - England
TA  - Vasc Med
JT  - Vascular medicine (London, England)
JID - 9610930
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Chronic Limb-Threatening Ischemia
MH  - *Drug-Eluting Stents
MH  - Femoral Artery/diagnostic imaging
MH  - Humans
MH  - Limb Salvage
MH  - *Paclitaxel/adverse effects
MH  - *Peripheral Arterial Disease/diagnostic imaging/therapy
MH  - Popliteal Artery
MH  - Retrospective Studies
MH  - Treatment Outcome
MH  - Vascular Patency
OTO - NOTNLM
OT  - chronic limb-threatening ischemia (CLTI)
OT  - drug-eluting stents
OT  - femoropopliteal
OT  - paclitaxel
OT  - peripheral artery disease (PAD)
EDAT- 2021/03/19 06:00
MHDA- 2022/03/11 06:00
CRDT- 2021/03/18 12:28
PHST- 2021/03/19 06:00 [pubmed]
PHST- 2022/03/11 06:00 [medline]
PHST- 2021/03/18 12:28 [entrez]
AID - 10.1177/1358863X20987894 [doi]
PST - ppublish
SO  - Vasc Med. 2021 Jun;26(3):267-272. doi: 10.1177/1358863X20987894. Epub 2021 Mar 
      18.